Analyst Kyle Mikson works at CANACCORD and is focused on the Healthcare sector with 85 price targets and ratings documented since 2019 spanning on 14 stocks. Previously, Kyle Mikson worked at CANTOR FITZGERALD. Analyst's average stock valuation to be materialised ratio is 24.15% with an average time for price targets to be met of 26.69 days.
Most recent stock forecast was given on PACB, Pacific Biosciences of California, Inc at 16-Nov-2022.
Kyle Mikson best performing recommendations are on TTOO (T2 BIOSYSTEMS, INC).
The best stock recommendation documented was for TTOO (T2 BIOSYSTEMS, INC) at 10/14/2022. The price target of $2 was fulfilled within 5 days with a profit of $0.32 (13.79%) receiving and performance score of 27.59.
Average potential price target upside